Top NYC, NY Companies With Best Stability & Growth (10,000+)

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Product Line Growth: Product capabilities have expanded with new cross‑media, cookieless and outcomes‑measurement offerings, a free self‑service brand‑lift tool in 2025, and an AI Search Lift product in 2026. This points to a broader addressable market and deeper product footprint.

Strategic Partnerships: Partnership activity includes being selected by publishers such as Vevo and DAX for outcomes and brand‑lift measurement. These relationships indicate ongoing commercial traction into 2025–26.

Diversified Customer Base: Commercial reach spans 500+ brands and 150+ agency/media partners, with earlier disclosures citing 800+ clients. This breadth across brands, agencies, and media companies reflects a diversified set of customer segments.

Market Expansion: Geographic expansion across Africa and Asia—including deployments in Namibia and Rwanda, continued projects in the Philippines, and a national initiative in Pakistan—signals a growing footprint. A partner-led reseller program active across several African and Asian markets further broadens reach.

Strategic Partnerships: Collaborations include AWS, Microsoft for Startups, NVIDIA Inception, Africa’s Talking, Mojaloop, and Living Map, alongside regional resellers with revenue-share arrangements. Joint work with FNA and a Gates Foundation-backed program for multiple low- and middle-income countries underline institutional alliances.

Innovation-Driven Growth: The platform has added workflow co-pilots, Voice APIs, database connectivity, and advanced chat/ticket categorization, with a steady 2026 release cadence. Voice AI for underserved languages and expansion into “Trust Layer” use cases illustrate an evolving, enterprise-focused roadmap.

Strong Revenue Growth: Revenue is described as rising at a very strong pace for multiple consecutive years, including a major surge in 2024. This sustained momentum indicates meaningful top-line expansion while advancing toward profitability.

Investor Backing & Capital Strength: Financing activity includes a late-stage equity round and substantial cumulative funding alongside expanded facilities. These signals point to continued access to capital that supports scaling credit and liquidity products.

Product Line Growth: Offerings have broadened beyond core banking into paycheck advances, fee-free overdraft, credit building, savings, teen accounts, and crypto. This expansion suggests more monetization paths and deeper engagement per customer.

Profitability: Digital operating income and adjusted EBITDA are rising, with margins improving (e.g., digital operating income up 56% in Q1 2026 and digital EBITDA margin expanding from 18% to 20%). Management also guided to mid‑to‑high single‑digit growth in digital adjusted EBITDA for 2026.

Strong Revenue Growth: Digital revenue shows a clear multi‑quarter uptrend: up 10% for full‑year 2025, +14% YoY in Q4 2025, +8% in Q1 2026, and +6% in Q2 2026. These gains indicate sustained momentum in the core digital segment despite broader headwinds.

Diversified Revenue Streams: Growth is coming from multiple digital lines—advertising, performance marketing, and licensing/other—and increasing revenue from sources less dependent on traditional website sessions. This mix shift helps offset pressure from search‑driven traffic declines.

Product Line Growth: Company updates point to a meaningful increase in product count in 2024, expanding the breadth of tradable products. Available evidence suggests this reflects operating-scale growth beyond hiring alone.

Market Expansion: The firm operates across Chicago, Boulder, New York, and Singapore, and signals expansion into new instruments and marketplaces domestically and globally. Physical office build-outs in Chicago further indicate an expanded footprint to accommodate growth.

Innovation-Driven Growth: Reported large increases in computing resources and major network upgrades in 2024 underscore ongoing investment in proprietary technology and infrastructure. Available evidence suggests these capacity gains are aimed at scaling trading capabilities.

Strong Revenue Growth: Available evidence indicates revenue scaled from roughly $800 million in 2023 to an estimated $1.2 billion annualized in 2024. The longer-term trajectory shows steady gains from 2017 onward, with scale signals like surpassing 1 billion meals delivered.

Profitability: Reporting describes more than $10 million in monthly profit, indicating a shift from pure growth to profitable scaling. This supports the view that the company can sustain operations while continuing to invest.

Market Expansion: Operations have broadened beyond DTC through personalized meal plans on Walmart.com and expansion via the Woof acquisition into canine wellness products. Continued veterinary research investment and substantial TV ad spend point to active reach and capability expansion.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Strong Revenue Growth: Estimates indicate annualized revenue rose sharply in 2024, with acceleration tied to GLP-1/obesity care. Evidence cites roughly $598M annualized revenue in 2024 versus about $360M in 2023.

Market Expansion: Recent launches and channel moves broadened reach, including nationwide availability of the Wegovy pill and a surge of new customers in early 2026. The platform reports helping millions of patients across nearly every U.S. county.

Strategic Partnerships: Direct integrations with major manufacturers (e.g., Novo Nordisk’s NovoCare for Wegovy and additional GLP-1 collaborations) position the company as a distribution/access channel. Novo Nordisk specifically described the company as part of its direct-to-patient expansion.

Strong Revenue Growth: Commerce Media is expanding at very high year-over-year rates across multiple quarters, and consolidated results recently returned to growth. The segment now represents a majority of revenue with a rising annualized run rate.

Strategic Partnerships: The partner network is widening with additional retailers and brands joining the platform. This expanding set of relationships appears to be fueling scale in the core business.

Future-Ready Strategy: The company is deliberately shifting from legacy operations toward a commerce‑media model that has delivered multi‑year acceleration and a rapidly growing share of mix. The trajectory suggests alignment with evolving market demand.

Strong Market Position & Advantage: PSA and sister brands are consistently portrayed as dominant in trading-card grading, with the portfolio spanning leading names across authentication and grading. This positioning is reinforced by consolidation of major competitors and broad category coverage.

Market Expansion: The company has expanded through acquisitions (including Beckett) and scaled its physical footprint with new and international grading locations. Capacity additions and geographic buildouts indicate active scaling of operations.

Investor Backing & Capital Strength: The business secured a sizable financing at a multibillion-dollar valuation and later committed substantial capital to expand PSA’s footprint, technology, and hiring. These actions signal strong access to capital to fund growth initiatives.

Strong Hiring & Retention: Hiring is expanding, with field-sales roles across 42 locations and a salaried New York position posted in early 2026. Company profiles also indicate roughly 30 employees and active recruiting, signaling a build-out of sales and product capacity.

Market Expansion: Geographic reach is widening through a multi-location field-sales organization covering dozens of U.S. markets. Independent company overviews further highlight this nationwide sales push as a core element of the expansion strategy.

Product Line Growth: The offering has broadened from POS into a fuller restaurant-technology platform, including mobile ordering/payments, kitchen displays, loyalty/marketing tools, and integrated payments. Added emphasis on automated cooking products and expansion into scheduling and inventory tools suggests an actively growing portfolio.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.